Late treatment study
et al., NEJM, doi:10.1056/NEJMoa2015301 (Peer Reviewed)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Study focused on remdesivir but with results for HC
Q in the supplementary appendix, showing 9% death with HC
Q versus 12% control, unadjusted relative risk uRR 0.78, p
death, ↓22.3%, p=0.46
Please send us corrections, updates, or comments.